Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

SELLASs Phase 3 REGAL trial of GPS in AML has reached its final-analysis milestone, and management has guided to preliminary topline results in November, making the pending readout the main focus. Bulls anticipate strong results and a possible short squeeze, while skeptics emphasize that the outcome is still unknown and warn of downside if the data disappoint; claims of a leak or certain success remain speculation.

Cerebras quarterly update is drawing attention for strong cloud growth and sharply higher forward revenue guidance, which sparked a rally and talk of a short squeeze. Traders are divided over the outlook: bulls focus on demand and growth prospects, while bears point to the larger-than-expected loss, heavy spending and questions about whether the gains can be sustained.

Candels prostate-cancer BLA timeline has been pushed to mid-2027 amid FDA discussions and assay refinements, prompting a sharp selloff. Traders debate whether this is a fixable manufacturing and regulatory delay with clinical data intact or a sign of execution and management concerns; the longer wait and potential dilution are also weighing on sentiment.

Anthropics Claude workplace tools, including Claude Sheets, have raised concerns that Microsofts Office and Copilot businesses could face new competition, weighing on sentiment toward MSFT. Traders disagree on the threat: some see a risk to Microsofts software moat, while others argue enterprise workflows are too deeply embedded for a quick switch; AI infrastructure spending and uncertain returns add to the debate.

Ciscos fiscal Q1 results drew attention after the company beat estimates and raised its full-year outlook, including a higher AI infrastructure revenue target. Traders were split over the muted, volatile share reaction: some welcomed the strong results, while others questioned margins and whether AI orders will convert into durable revenue.

Traders are reacting to a report that Samsung is in discussions to acquire Modine, with speculation about a potential buyout premium driving excitement and debate over the offer price. The acquisition remains unconfirmed in the discussion.

A sharp selloff followed Cardinals Q3 results, as weaker project margins, a reported loss and withdrawal of its 2026 outlook raised concerns about cost controls and management; the CFOs planned departure added to the uncertainty. Traders are split between viewing the decline as an overreactionciting the companys cash position and authorized buybackand fearing further losses or deeper operational problems.

A Q3 revenue miss and sequential slowdown in Anktiva sales have fueled a sharp selloff, with investors also criticizing the lack of an earnings call or clear guidance and debating cash needs and dilution risk. Bulls point to the positive BCG-nave trial result, expanded bladder-cancer label and sepsis research, but question whether those developments will translate into faster sales growth.

Applied Materials quarterly results and forward guidance dominate discussion: traders cite a strong earnings beat and upbeat outlook, but are frustrated that the shares barely responded and later fell. The reaction has sparked a sell-the-news debate, with some investors calling the good news priced in or questioning the guidances comparability, while others remain positive on chip-equipment demand.

Nus Q3 earnings are driving discussion: traders point to strong growth and improving efficiency, while skeptics cite mixed results and worsening credit quality, including higher delinquencies. Reactions are split between buyers calling the quarter solid and holders frustrated by the muted share-price response.